Shitara Toshiji, Shimada Akira, Hanada Ryoji, Matsunaga Tadashi, Kawa Keisei, Mugishima Hideo, Sugimoto Tohru, Mimaya Jun-ichi, Manabe Atsushi, Tsurusawa Masahito, Tsuchida Yoshiaki
Department of Hematology/Oncology, Gunma Children's Medical Center, Seta-gun, Gunma, Japan.
Pediatr Hematol Oncol. 2006 Mar;23(2):103-10. doi: 10.1080/08880010500457152.
Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuro-blastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.
伊立替康有望成为一种用于儿童实体瘤的新药。16例复发实体瘤患儿接受伊立替康治疗，剂量为180mg/m²/天，连续给药3天，停药25天后重复一次。他们原来的肿瘤类型中，7例为神经母细胞瘤，3例为横纹肌肉瘤，2例为肾母细胞瘤和未分化肉瘤，1例为原始神经外胚层肿瘤，1例为平滑肌肉瘤。试验时的平均年龄为6岁。5例（31.3%）（神经母细胞瘤、横纹肌肉瘤、肾母细胞瘤、未分化肉瘤和平滑肌肉瘤）获得部分缓解，另外2例肿瘤标志物下降。伊立替康似乎很有前景，可能会被纳入一线治疗。
